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LETTER TO THE EDITORReduced-Intensity Allografting
in Childhood Acute
Lymphoblastic Leukemia
We read with interest the article by Verneris et al.
[1], concerning reduced-intensity conditioning (RIC)
for allografting children with acute lymphoblastic leu-
kemia (ALL). In their article, they gather data of 38
such patients. Despite the fact that they refer to
some of our experience [2], they fail to include
other articles from our group that include children
with ALL allografted with a RIC regimen [3-6]. Since
1998, in 2 institutions within Mexico (Centro de
Hematologia y Medicina Interna de Puebla and
Hospital Universitario de Nuevo Leon), we have
allografted 44 children with ALL, using our RIC
regimen that employs fludarabine, cyclophos-
phamide, and busulfan [2-5]. The median age is 6
years (range: 1-16), 13 females. In this group, we have
allografted 14 patients in first complete remission
(CR) and 30 in second or beyond CR. The median
overall-survival (OS) of these 44 patients was 10
months, whereas the 85-month OS survival was 18%.
Results for patients in first CR were substantially
better than those obtained in relapsed individuals
(45%versus 5%OSat 85months) (see Figure 1).These
data are not different from those informed by Verneris
et al. [1], and suggest that the malignant cells of someFigure 1. Overall survival (OS) of the 44 children with acute lymphoblastic
complete remission (CR) (n 5 14) or in second or beyond CR (n 5 30).children with ALL may be sensitive to the graft-
versus-leukemia effect, and that there is still a role for
allografting children with ALL. These results are
clearly inferior to those obtained by us using the same
RIC in patients with chronic myeloid leukemia
(CML) [7] or acute myelogenous leukemia (AML)
[8], where the graft-versus-leukemia effect is more
clear. Because the late effects of allografting children
seem to be less frequent and less severe when using
RIC regimens, more groups are engaging in this prac-
tice, which was initially conducted and published by
our group in 1993 [3].REFERENCES
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